Literature DB >> 26670126

Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis.

Esther Korpershoek1, Djamailys Koffy1, Bert H Eussen1, Lindsey Oudijk1, Thomas G Papathomas1, Francien H van Nederveen1, Eric J T Belt1, Gaston J H Franssen1, David F J Restuccia1, Niels M G Krol1, Rob B van der Luijt1, Richard A Feelders1, Rogier A Oldenburg1, Wilfred F J van Ijcken1, Annelies de Klein1, Wouter W de Herder1, Ronald R de Krijger1, Winand N M Dinjens1.   

Abstract

CONTEXT: Familial pheochromocytoma (PCC) has been associated with germline mutations in 16 genes. Here we investigated three siblings presenting with bilateral pheochromocytomas. In addition, the index patient also exhibited renal oncocytoma and erythrocytosis, whereas the second sibling presented with a lymph node metastasis.
DESIGN: First, single-nucleotide polymorphism array and exome sequencing were performed on germline and PCC-derived DNA to identify genomic alterations in the index patient. Second, alterations were confirmed and validated by Sanger sequencing, analyzed by (multiplexed) PCR to determine the loss of the wild-type allele, and investigated by immunohistochemistry in the tumors of the three siblings.
RESULTS: The index patient's germline DNA revealed a large complex genomic alteration encompassing the intragenic and promoter regions of Myc-associated factor X (MAX) and alpha-(1,6)-fucosyltransferase (FUT8). In all three siblings the MAX alteration was confirmed, and the loss of the wild-type MAX and FUT8 alleles was demonstrated in all tumors. Uniparental disomy of chromosome 14q, previously demonstrated as a hallmark for MAX-related PCC, was shown in the index patient's PCC by single-nucleotide polymorphism array. Loss of MAX and FUT8 protein expression was demonstrated by immunohistochemistry in the tumors from the three siblings.
CONCLUSIONS: Our results indicate that large genomic deletions of MAX should be considered in familial and bilateral PCC with prior negative testing for gene mutations. In addition, our results confirm that MAX is a tumor suppressor gene for renal oncocytomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26670126     DOI: 10.1210/jc.2015-2592

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  PRECISION MEDICINE IN ADRENAL DISORDERS: THE NEXT GENERATION.

Authors:  Hans K Ghayee; Aaron I Vinik; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

Review 2.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 3.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

4.  18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma.

Authors:  David Taïeb; Abhishek Jha; Carole Guerin; Ying Pang; Karen T Adams; Clara C Chen; Pauline Romanet; Philippe Roche; Wassim Essamet; Alexander Ling; Martha M Quezado; Frédéric Castinetti; Fréderic Sebag; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

5.  PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.

Authors:  Maria Currás-Freixes; Elena Piñeiro-Yañez; Cristina Montero-Conde; María Apellániz-Ruiz; Bruna Calsina; Veronika Mancikova; Laura Remacha; Susan Richter; Tonino Ercolino; Natalie Rogowski-Lehmann; Timo Deutschbein; María Calatayud; Sonsoles Guadalix; Cristina Álvarez-Escolá; Cristina Lamas; Javier Aller; Julia Sastre-Marcos; Conxi Lázaro; Juan C Galofré; Ana Patiño-García; Amparo Meoro-Avilés; Judith Balmaña-Gelpi; Paz De Miguel-Novoa; Milagros Balbín; Xavier Matías-Guiu; Rocío Letón; Lucía Inglada-Pérez; Rafael Torres-Pérez; Juan M Roldán-Romero; Cristina Rodríguez-Antona; Stephanie M J Fliedner; Giuseppe Opocher; Karel Pacak; Esther Korpershoek; Ronald R de Krijger; Laurent Vroonen; Massimo Mannelli; Martin Fassnacht; Felix Beuschlein; Graeme Eisenhofer; Alberto Cascón; Fátima Al-Shahrour; Mercedes Robledo
Journal:  J Mol Diagn       Date:  2017-05-25       Impact factor: 5.568

Review 6.  Normal and Neoplastic Growth Suppression by the Extended Myc Network.

Authors:  Edward V Prochownik; Huabo Wang
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

Review 7.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 8.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 9.  Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma.

Authors:  Veronica K Y Cheung; Anthony J Gill; Angela Chou
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 10.  Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.

Authors:  C Christofer Juhlin
Journal:  Endocr Pathol       Date:  2021-03-25       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.